Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Liabilities and Shareholders Equity (2023 - 2025)

CG Oncology filings provide 3 years of Liabilities and Shareholders Equity readings, the most recent being $791.6 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 4.87% to $791.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 billion, a 20.42% increase, with the full-year FY2025 number at $791.6 million, up 4.87% from a year prior.
  • Liabilities and Shareholders Equity hit $791.6 million in Q4 2025 for CG Oncology, up from $729.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $791.6 million in Q4 2025 to a low of $199.3 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 3 years was $701.4 million (2025), compared with a mean of $622.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 278.72% in 2024 and later rose 4.87% in 2025.
  • CG Oncology's Liabilities and Shareholders Equity stood at $199.3 million in 2023, then surged by 278.72% to $754.8 million in 2024, then rose by 4.87% to $791.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $791.6 million (Q4 2025), $729.9 million (Q3 2025), and $701.4 million (Q2 2025) per Business Quant data.